Substances present in the body such as polyreactive antibodies or heterophiles, or human anti-animal antibodies coupled with some other binding proteins can cause interference due to reactions between analyte and reagent antibodies in immunoassay. These substances have the potential to change the concentration of the analytic or alter antibody binding resulting in immunoassay interference. This alterations can lead to the misinterpretation of the diagnostic outcomes by the laboratory further causing inappropriate selection of course of treatment being given by the healthcare professionals. Interference may cause an impact over a wide range of analytes measured by immunoassay including hormones, tumor markers, drugs, cardiac troponin and microbial serology. Although, the use of interference blockers can reduce the alterations as the interference is low in assays containing blocking agents that neutralize or inhibit the interference.
Immunoassay interference blocker kit consists of reagents that are specifically designed to that neutralize or inhibit the interference and prevent faulty results that enhances the overall assay performance as well.
COVID – 19 scenario analysis:
- The COVID-19 pandemic has emerged as a humanitarian as well as economic crisis, creating strain on the society and affecting millions of people and businesses
- Industry closures and people are asked to stay in their homes which has cause taken a huge toll in terms of money and economic growth
- Over 4 million people affected globally, with 300 thousand losing their lives due to SARS-CoV-2
- Healthcare organizations are already working in battle mode, preparing new plans to respond growing COVID-19 patients, right from sourcing rapid diagnosing kits to sufficient PPE kits for workers
- Due to diversion of medical field towards treating COVID-19, the funding to R&D activities related to immunoassay interference blocker has been reduced and this segment have to face negligence subsequently causing negative impact on immunoassay interference blocker market
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
Heavy investments in research and development activities related to immunoassay interference inhibitors with the motive of gaining accuracy in clinical diagnosis, to reduce the degree of errors for the results of biochemical analysis and advancement in blocker used for interference and kits manufacturing are the major drivers for growing immunoassay interference blocker market. The U.S. industry spend approximately 2-3% in research & development activities related to immunoassay interference inhibitors. Furthermore, constant clinical efforts and research studies emphasized on improvising diagnosis of various diseases and disorders in order to provide efficient treatment and care to patients, advancement in the new drug discoveries and diagnostics biologics further catalyzes the growth of this market. Laboratory diagnostic results, including immunoassay results, impact and lead about 70 percent of clinical healthcare decisions related to further treatment of the aliment. Inaccurate diagnostic results due to antibody interference increase the risk of irrelevant and sometimes irreversible treatment.
Rising focus of the major industry players on bringing new technologies and kits that could aid in effective diagnosis which would emphasize on progressive patterns of cancer and other chronic, viral and infectious diseases and better patient survival rate coupled with advances that aid in amplifying the capabilities of research and development to propel the immunoassay interference blocker market over the coming years.
Immunoassay interference prevalence depends on the endogenous substance interference type upon and the analyte and assay. However, implementation of inhibitor in the patient’s diagnostic sample fails to restrict full range of protein interference and hence cannot bolster on full accuracy of the results. This can have a negative impact on immunoassay interference locker market and impede the growth.
Increasing prevalence of chronic and viral diseases and healthcare expenditure to boost the growth
According to the statistics published by world health organization (WHO), there has been immense increase in chronic diseases worldwide. In 2001, chronic diseases accounted for almost 60% of the 56.5 million reported deaths with approximately 46% of the burden of disease worldwide. Non-communicable diseases (NCDs) are expected to increase upto 57% by 2020. The geriatric population is expected to rise by 22% by the year 2050, according to WHO. The number of infectious & non-infectious diseases has been rising simultaneously. According to the WHO, by 2018, the number of people infected with this virus is 75 million right from the beginning of this pandemic and around 32 million people have died because of this disease. Additionally, by the end of2018, around 37.9 million people were living with HIV. The growth in various diseases would ensure market development for this market.
Organization for Economic Co-operation and Development (OECD) survey report, stated in 2018 average per capita health expenditure in the U.S. was about USD 10,586. Thus, the rising healthcare expenditure would also contribute to the global immunoassay interference blocker market.
The efforts taken to increase the accuracy of diagnostic results, increasing incidences of chronic diseases and increasing healthcare expenditure are factors that would facilitate the market growth.
North American region dominates the market
North America is expected to lead the reprocessed medical devices market throughout. The dominance is due to factors like rise in the global prevalence of cardiovascular diseases and higher adoption of technology in the region. According to Centers for Disease Control and Prevention, cardiac diseases are a leading cause of death in American men. As per the American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases resulting higher demand for affordable treatment and cost effective therapies is propelling the market in the United States. Drastic rise in healthcare expenditure and high strain to get better health outputs at lower costs, availability of a well-developed infrastructure and presence of major industry are the other factors fostering the market in the near future.
Key benefits of the report:
- This study presents the analytical depiction of the global immunoassay interference blocker industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global immunoassay interference blocker market share.
- The current market is quantitatively analysed to highlight the global immunoassay interference blocker market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global immunoassay interference blocker market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Immunoassay interference blocker Market research report:
- What are the leading market players active in the immunoassay interference blocker market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Immunoassay Interference Blocker Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Meridian Bioscience, Abcam, AMS Biotechnology, Scantibodies Laboratory, Sysmex Corporation, Roche Diagnostics, Thermo Fisher Scientific, Rockland Immunochemicals, Aviva Systems Biology, Bio-Rad Laboratories |
 Other Players | Qiagen N.V |
Loading Table Of Content...
